At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
YF476 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus
In Brief
A Phase 2 clinical trial evaluating YF476 and YF476 placebo for Barrett's Esophagus. Completed, enrolled 27 participants across 2 sites in 2 countries.
Detailed Summary
A phase 2, randomised, double-blind, out-patient trial to determine if YF476 is a safe and effective treatment in patients with Barrett's esophagus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBarrett's Esophagus
CountriesUnited Kingdom, United States
CollaboratorsColumbia University, University of Cambridge
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedNov 2015
Primary CompletionNov 2017
Study CompletionDec 2017
TodayJul 2026
First PostedNov 5, 2015
Enrollment StartMay 15, 2013
Primary CompletionNov 28, 2017
Study CompletionDec 27, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.7 years ago
Interventions
YF476drug
gastrin receptor antagonist
YF476 placebodrug
placebo